A functional polymorphism of TGFBR2 is associated with risk of breast cancer with ER+, PR+, ER+PR+ and HER2- expression in women

Oncology Letters

Volumn 2, Issue 4, 2011, Pages 653-658

  Zhang, Mei ^a,b   Guo, Ling Ling ^a   Cheng, Zhongqin ^b   Liu, Reng Yun ^b   Lu, Yufeng ^a   Qian, Qian ^b   Lei, Zhe ^b   Zhang, Hong Tao ^b  

^a THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

Breast cancer; Polymorphism; Risk; TGFB1; TGFBR2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PARAFFIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE PREDISPOSITION; DNA POLYMORPHISM; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; RISK ASSESSMENT;

EID: 79958060205     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.312     Document Type: Article

References (28)

1. Ziegler RG, Anderson WF and Mh G: Increasing breast cancer incidence in China: the numbers add up. JNCI 100: 1339-1341, 2008.
2. Linos E, Rosner BA and Linos K: Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis. JNCI 100: 1352-1359, 2008.
3. Massague J and Chen YG: Controlling TGF-beta signaling. Genes Dev 14: 627-644, 2000.
4. Gobbi H, Arteaga CL, Jensen RA, Simpson JF, Dupont WD, Olson SJ, Schuyler PA, Plummer WD Jr and Page DL: Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in situ and invasive carcinomas. Histopathology 36: 168-177, 2000.
5. Gobbi H, Dupont WD, Simpson JF, Plummer WD Jr, Schuyler PA, Olson SJ, Arteaga CL and Page DL: Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst 91: 2096-2101, 1999.
6. Daniel CW and Robinson SD: Regulation of mammary growth and function by TGF-beta. Mol Reprod Dev 32: 145-151, 1992.
7. Barcellos-Hoff MH and Ewan KB: Transforming growth factor-beta and breast cancer: mammary gland development. Breast Cancer Res 2: 92-99, 2000.
8. White RL: Tumor suppressing pathways. Cell 92: 591-592, 1998.
9. Cambien F, Ricard S, Troesch A, Mallet C, Generenaz L, Evans A, Arveiler D, Luc G, Ruidavets JB and Poirier O: Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study. Hypertension 28: 881-887, 1996.
10. Seijo ER, Song H, Lynch MA, Jennings R, Qong X, Lazaridis E, Muro-Cacho C, Weghorst CM and Munoz-Antonia T: Identification of genetic alterations in the TGFbeta type II receptor gene promoter. Mutat Res 483: 19-26, 2001.
11. Zhang Y, Liu B, Jin M, Ni Q, Liang X, Ma X, Yao K, Li Q and Chen K: Genetic polymorphisms of transforming growth factor-beta1 and its receptors and colorectal cancer susceptibility: a population-based case-control study in China. Cancer Lett 275: 102-108, 2009.
12. Dunning AM, Ellis PD, McBride S, et al: A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 63: 2610-2615, 2003.
13. Onitilo AA, Engel JM, Greenlee RT and Mukesh BN: Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7: 4-13, 2009.
14. Kaklamani VG, Baddi L, Liu J, et al: Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Cancer Res 65: 3454-3461, 2005.
15. Paiva CE, Drigo SA, Rosa FE, Moraes Neto FA, Caldeira JR, Soares FA, Domingues MA and Rogatto SR: Absence of transforming growth factor-beta type II receptor is associated with poorer prognosis in HER2-negative breast tumours. Ann Oncol 21: 734-740, 2010.
16. Banerjee SK, Makdisi WF, Weston AP, Mitchell SM and Campbell DR: Microwave-based DNA extraction from paraffin-embedded tissue for PCR amplification. Biotechniques 18: 768-770; 772-763, 1995.
17. Sato Y, Sugie R, Tsuchiya B, Kameya T, Natori M and Mukai K: Comparison of the DNA extraction methods for polymerase chain reaction amplification from formalin-fixed and paraffin-embedded tissues. Diagn Mol Pathol 10: 265-271, 2001.
18. Qi X, Zhang F, Yang X, Fan L, Zhang Y, Chen L, Zhou Y, Chen X, Zhong L and Jiang J: Transforming growth factor-beta1 polymorphisms and breast cancer risk: a meta-analysis based on 27 case-control studies. Breast Cancer Res Treat 122: 273-279, 2010.
19. Hishida A, Iwata H, Hamajima N, Matsuo K, Mizutani M, Iwase T, Miura S, Emi N, Hirose K and Tajima K: Transforming growth factor B1 T29C polymorphism and breast cancer risk in Japanese women. Breast Cancer 10: 63-69, 2003.
20. Cox DG, Penney K, Guo Q, Hankinson SE and Hunter DJ: TGFB1 and TGFBR1 polymorphisms and breast cancer risk in the Nurses' Health Study. BMC Cancer 7: 175, 2007.
21. Jin Q, Hemminki K, Grzybowska E, Klaes R, Soderberg M, Zientek H, Rogozinska-Szczepka J, Utracka-Hutka B, Pamula J, Pekala W and Forsti A: Polymorphisms and haplotype structures in genes for transforming growth factor beta1 and its receptors in familial and unselected breast cancers. Int J Cancer 112: 94-99, 2004.
22. Jin G, Wang L, Chen W, Hu Z, Zhou Y, Tan Y, Wang J, Hua Z, Ding W, Shen J, Zhang Z, Wang X, Xu Y and Shen H: Variant alleles of TGFB1 and TGFBR2 are associated with a decreased risk of gastric cancer in a Chinese population. Int J Cancer 120: 1330-1335, 2007.
23. Jin G, Deng Y, Miao R, Hu Z, Zhou Y, Tan Y, Wang J, Hua Z, Ding W, Wang L, Chen W, Shen J, Wang X, Xu Y and Shen H: TGFB1 and TGFBR2 functional polymorphisms and risk of esophageal squamous cell carcinoma: a case-control analysis in a Chinese population. J Cancer Res Clin Oncol 134: 345-351, 2008.
24. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R and Dickson RB: Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417-428, 1987.
25. Wrana JL, Attisano L, Wieser R, Ventura F and Massague J: Mechanism of activation of the TGF-beta receptor. Nature 370: 341-347, 1994.
26. Buck M, von der Fecht J and Knabbe C: Antiestrogenic regulation of transforming growth factor beta receptors I and II in human breast cancer cells. Ann NY Acad Sci 963: 140-143, 2002.
27. Arteaga CL, Tandon AK, von Hoff DD and Osborne CK: Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res 48: 3898-3904, 1988.
28. Kalkhoven E, Roelen BA, de Winter JP, Mummery CL, van den Eijnden-van Raaij AJ, van der Saag PT and van der Burg B: Resistance to transforming growth factor beta and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Differ 6: 1151-1161, 1995.